2Shepherd FA Bezjak A 冯玉麟 刘春涛 译.老年小细胞肺癌的治疗[A]..肺癌[M].北京:人民卫生出版社,2002.996-1003.
3De Rijke JM, Schouten LJ, Schouten HC, et al. Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, The Netherlands [ J ].Ann Oncol,1996,7(7) :677-685.
4Joel SP, Shah R, Slevin ML. Etoposide dosage and phannacodynamics[ J]. Cancer Chemother Pharmacol,1994,34(Suppl) :69-75.
5Slevin ML, Clark PI, Osborne R J, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer[J]. J Clin Oncol,1989,7(9) :1333-1340.
6Clark PI,Slevin ML,Joel SP,et al. A randomized trial of two etoposide schedules in small-cell lung cancer:the influence of pharmacokinetics on efficacy and toxicity [ J]. J Clin Oncol, 1994,12 (7) :1427-1435.
7Hande KR. The importance Of drug scheduling in cancer chemotherapy : etoposide as an example [ J ]. The Oneologist, 1996,1 ( 4 ) :234 -239.
8Johnson DH. Management of small cell lung cancer: current state of the art. Chest[ J]. 1999,116( Suppl 6) :525-530.
9Larive S, Bombaron P, Riou R, et al. Carboplatin-etoposide combination in small cell lung cancer patients older than 70 years :a phase Ⅱ trial [ J ]. Lung Cancer,2002,35 ( 1 ) : 1-7.
10Faylona EA, Loehrer PJ, Ansari R, et al. Phase Ⅱ study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial.[J]. J Clin Oncol,1995,13(9) :1209-1214.
2Kim E,Biswas T,Bakaki P,et al.Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer(LS-SCLC)in the elderly population(age>65 years)using national SEERMedicare data[J].Pract Radiat Oncol,2016,28:13-18.
3Cristea S,Sage J.Is the canonical RAF/MEK/ERK signaling pathway a therapeutic target in SCLC?[J].J Thorac Oncol,2016,28:30383-30385.
4Wagner H.Should all patients with SCLC receive prophylactic cranial irradiation if they have responded to treatment?The time has come to improve on a former standard[J].Clin Adv Hematol Oncol,2015,13:729-733.
